Biotechnology:-In-Vitro-&-In-Vivo-Diagnostic-Substances (20)
| Company | Ticker | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Lucira Health Inc. | LHDX | 0% | 307% | -99% | 0% | 0% |
| ALX Oncology Holdings Inc. | ALXO | -88% | 32% | -48% | -74% | 0% |
| Berkeley Lights Inc. | BLI | 0% | -63% | -85% | -80% | 0% |
| VolitionRX Limited | VNRX | 0% | 0% | -34% | -20% | -15% |
| OncoCyte Corporation | OCX | 0% | -39% | -85% | -11% | 12% |
| Navidea Biopharmaceuticals Inc | NAVB | 0% | 0% | -74% | -53% | 75% |
| Trinity Biotech plc | TRIB | 4% | -57% | -31% | -63% | 261% |
| Quotient Limited | QTNT | 0% | 0% | -85% | -50% | -45% |
| Quidel Corporation | QDEL | 0% | 0% | -32% | -25% | 143% |
| Nymox Pharmaceutical Corporation | NYMX | 0% | -33% | -72% | -58% | 15% |
| Neogen Corporation | NEOG | -36% | 32% | -66% | -43% | 22% |
| Myriad Genetics Inc | MYGN | -21% | 32% | -47% | 40% | -27% |
| Meridian Bioscience Inc | VIVO | 0% | 2% | 65% | 7% | 93% |
| ImmuCell Corporation | ICCC | -9% | -17% | -24% | 34% | 19% |
| IDEXX Laboratories Inc | IDXX | -23% | 36% | -38% | 32% | 92% |
| Celldex Therapeutics Inc | CLDX | -33% | -11% | 15% | 121% | 696% |
| ARCA biopharma Inc | ABIO | 44% | -28% | 6% | -44% | -30% |
| Achieve Life Sciences Inc | ACHV | 9% | 67% | -69% | -3% | 1482% |
| Intellia Therapeutics Inc. | NTLA | -52% | -13% | -71% | 123% | 268% |
| Lantheus Holdings Inc. | LNTH | 49% | 22% | 76% | 114% | -33% |